title: [Prognostic analysis of 51 cases of primary nodal diffuse large B-cell lymphomas].
abstract: OBJECTIVE
  To explore the prognostic factors of primary nodal diffuse large B-cell lymphomas (N-DLBCL).
  
  
  METHODS
  According to the 2001 WHO classification of tumors of hematopoietic and lymphoid tissue, 51 cases of primary N-DLBCL were collected for clinical data analysis and immunohistochemical assay. Antibodies used for study were anti-CD20, CD79alpha, CD45RO, CD3, Bcl-2, Ki-67, CD30, CD15, kappa, lambda, Cyclin D1, TdT, GFAP, CK, MPO. The survival data was analyzed.
  
  
  RESULTS
  Of the 51 cases of N-DLBCLs, 40 were reclassified as centroblastic, 3 B-immunoblastic, 1 T-cell/histiocytes rich, 2 B-cell anaplastic large cell, 1 plasmablastic, and 4 unclassified. Expression of Bcl-2 oncoprotein was observed in 24 cases (47.1%). The median Ki-67 index was 50.0% and the index more than 40% was found in 35 cases (68.6%). Survival analysis of 35 cases had follow up data showed that the 2 year and 5-year overall survival (OS) rates were 48.54% and 35.30%, respectively. The 5-year OS rates patients with International Prognosis Index (IPI) >/= 3 was lower than that with IPI < 3 (P < 0.01). The 5-year OS rates for patients with B symptoms was lower than that without B symptoms (P < 0.05). The 5-year OS rates for patients with Ki-67 index more than 40% was lower than that with less than 40% (P < 0.05). The expression of Bcl-2 oncoprotein was uncorrelated to prognosis (P > 0.05).
  
  
  CONCLUSIONS
  IPI, B symptoms and Ki-67 index are the prognostic factors for patients with N-DLBCL.
authors.affiliation: Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Li
authors.forename: Gan-di
authors.initials: GD
authors.lastname: Li
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Liu
authors.forename: Wen-Yan
authors.initials: WY
authors.lastname: Zhang
authors.forename: Feng-Yuan
authors.initials: FY
authors.lastname: Li
authors.forename: Dian-Ying
authors.initials: DY
authors.lastname: Liao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018951:Antigens, CD20 / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D019938:Cyclin D1 / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000032:analysis; D019394:Ki-67 Antigen / Q000032:analysis; D017493:Leukocyte Common Antigens / Q000032:analysis; D016256:Lewis X Antigen / Q000032:analysis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D018951:Antigens, CD20; D017730:Ki-1 Antigen; D019394:Ki-67 Antigen; D016256:Lewis X Antigen; D019938:Cyclin D1; D017493:Leukocyte Common Antigens